Hypersensitivity pneumonitis related to imatinib mesylate.

作者信息

Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, Socié G, Calvo F, Gluckman E, Ribaud P, Rousselot Ph, Tazi A

出版信息

J Clin Oncol. 2002 Oct 15;20(20):4271-2. doi: 10.1200/JCO.2002.99.179.

DOI:10.1200/JCO.2002.99.179

PMID:12377975

Abstract

摘要

相似文献

Hypersensitivity pneumonitis related to imatinib mesylate.

J Clin Oncol. 2002 Oct 15;20(20):4271-2. doi: 10.1200/JCO.2002.99.179.

Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.

Am J Hematol. 2005 May;79(1):80-1. doi: 10.1002/ajh.20319.

Interstitial pneumonitis during imatinib therapy.

Br J Haematol. 2004 May;125(4):420. doi: 10.1111/j.1365-2141.2004.04833.x.

Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.

J Clin Oncol. 2003 Jan 1;21(1):172-3. doi: 10.1200/JCO.2003.01.052.

Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.

Hong Kong Med J. 2014 Oct;20(5):464.e2. doi: 10.12809/hkmj134084.

Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.

Am J Hematol. 2005 May;79(1):79-80. doi: 10.1002/ajh.20274.

[A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].

Ter Arkh. 2010;82(2):59-61.

Histological features of acute hepatitis after imatinib mesylate treatment.

Leukemia. 2003 May;17(5):978-9. doi: 10.1038/sj.leu.2402910.

Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.

Pol Arch Med Wewn. 2013;123(5):251-2.

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.

Br J Haematol. 2003 Mar;120(6):1091-2. doi: 10.1046/j.1365-2141.2003.04208_3.x.

引用本文的文献

Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database.

Drugs Real World Outcomes. 2025 Sep 2. doi: 10.1007/s40801-025-00515-9.

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.

World J Gastroenterol. 2018 Dec 14;24(46):5189-5202. doi: 10.3748/wjg.v24.i46.5189.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28.

Nilotinib-induced interstitial lung disease.

Int J Hematol. 2013 Sep;98(3):361-5. doi: 10.1007/s12185-013-1398-5. Epub 2013 Jul 23.

Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.

Int J Hematol. 2013 Feb;97(2):299-300. doi: 10.1007/s12185-012-1250-3. Epub 2012 Dec 28.

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.

Int J Hematol. 2011 Oct;94(4):361-371. doi: 10.1007/s12185-011-0921-9. Epub 2011 Sep 8.

A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.

Int J Hematol. 2010 Dec;92(5):777-8. doi: 10.1007/s12185-010-0729-z. Epub 2010 Nov 26.

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Ther Clin Risk Manag. 2008 Feb;4(1):163-87.

Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Can Respir J. 2008 May-Jun;15(4):211-6. doi: 10.1155/2008/305234.

Diagnostic strategy in cancer patients with acute respiratory failure.

Intensive Care Med. 2006 Jun;32(6):808-22. doi: 10.1007/s00134-006-0129-2. Epub 2006 Apr 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验